Viagra for cancer? Scientists discover surprising link between Sildenafil and tumour spread
New Delhi: For nearly three decades, Viagra has been synonymous with treating erectile dysfunction. But now, the little blue pill is making headlines for an entirely different reason. Scientists have uncovered evidence suggesting that sildenafil, the drug’s active ingredient, may be able to slow the spread of cancer by starving tumour cells of a crucial nutrient. The findings have sparked excitement among cancer researchers because the drug is already widely used, well understood and relatively inexpensive. However, while the research is promising, scientists are also urging caution: the evidence is still at an early stage, and Viagra is not a cancer treatment.
Could Viagra’s active ingredient fight cancer
The research, published in the peer-reviewed journal Cancer Research, was led by scientists at the Weizmann Institute of Science in Israel. Rather than discovering that sildenafil directly kills cancer cells, the team identified a previously unknown biological mechanism through which the drug may reduce metastasis – the process by which cancer spreads from its original site to other organs.
Metastasis is responsible for the majority of cancer-related deaths worldwide, making it one of the biggest challenges in oncology. If researchers can prevent or slow this process, it could significantly improve patient outcomes.
How does sildenafil appear to work against cancer
Sildenafil belongs to a class of drugs called PDE5 inhibitors, which work by increasing levels of a signalling molecule known as cyclic guanosine monophosphate (cGMP). This is the same mechanism that helps relax blood vessels and improve blood flow in people with erectile dysfunction.
The new study suggests cGMP has another important function.
Researchers found that elevated cGMP can bind to a cholesterol-transport protein called NPC1, trapping cholesterol inside cellular compartments known as lysosomes. As a result, cancer cells have less access to cholesterol – a vital building block they need to grow, divide and, most importantly, spread to distant organs.
Without sufficient cholesterol, metastatic cancer cells appear to struggle to survive and establish new tumours.
Research wasn’t limited to laboratory experiments
One of the strengths of the study is that it combined multiple forms of evidence.
The scientists examined:
- Mouse models of cancer
- Human cancer cells grown in laboratories
- Medical records spanning around 20 years from approximately 5 million patients enrolled in Israel’s Clalit Health Services database
Across these analyses, sildenafil consistently showed signs of being associated with reduced cancer progression and improved survival outcomes.
A surprising boost when combined with statins
Perhaps the most intriguing finding was that patients taking both sildenafil and statins, medicines commonly prescribed to lower cholesterol, appeared to have even better survival outcomes than those taking sildenafil alone.
Researchers believe the two drugs may attack cholesterol availability from different directions:
- Sildenafil blocks cancer cells from accessing stored cholesterol.
- Statins reduce the body’s production of new cholesterol.
Together, they may deprive tumour cells of a resource they rely on for metastasis. However, researchers stress that this observation comes from patient data and does not prove that the drug combination directly improves survival. Only controlled clinical trials can establish cause and effect.
Why are scientists excited
Drug development is often a lengthy and expensive process, sometimes taking more than a decade before a medicine reaches patients.
Because sildenafil is already an approved medication with a well-established safety profile, researchers see it as an attractive candidate for drug repurposing, finding new uses for existing medicines.
Repurposed drugs can often move into clinical trials faster than entirely new compounds, potentially accelerating the development of new treatment strategies if future studies confirm their effectiveness. Previous research has also explored sildenafil’s potential to enhance chemotherapy, improve immune responses and influence tumour biology, although none of these approaches has yet become standard cancer treatment.
But there’s an important catch
Despite the excitement, the findings should not be interpreted as evidence that Viagra cures cancer.
The researchers themselves emphasise several limitations:
- Much of the evidence comes from laboratory studies and animal models.
- The patient data is observational, meaning it identifies associations rather than proving sildenafil caused better outcomes.
- Large, carefully designed clinical trials are still needed to determine whether the drug is effective, which cancers benefit most, what doses are required and whether the benefits outweigh any risks in cancer patients.
Should cancer patients take Viagra
No.
Doctors strongly advise against self-medicating with sildenafil in the hope of treating cancer. Viagra remains approved primarily for erectile dysfunction and pulmonary arterial hypertension, and it has not been approved as a cancer therapy.
Taking sildenafil without medical supervision may be inappropriate or unsafe for some individuals, particularly those taking nitrate medications or with certain cardiovascular conditions. Cancer treatment decisions should always be made with an oncologist.
The latest research offers a fascinating glimpse into how a familiar drug could one day play an unexpected role in cancer care. By disrupting cancer cells’ access to cholesterol, sildenafil may help slow metastasis—a discovery that opens a promising new avenue for research.
However, the science is still in its early stages. While the findings are encouraging and highlight the potential of repurposing existing medicines, much more research is needed before Viagra—or its active ingredient, sildenafil—can be considered part of routine cancer treatment. For now, it’s an exciting scientific development rather than a clinical breakthrough.